Nikel Lab (DTU Biosustain) - Synthetic Methylotrophy Platform

Nikel Lab at the Novo Nordisk Foundation Center for Biosustainability (DTU) has published a bioRxiv preprint, 'Seven mutations unlock strict synthetic methylotrophy in engineered Pseudomonas putida' (Puiggene, Fricano, Rossi et al., Nikel PI, 2026 preprint), describing implementation of a synthetic serine-threonine cycle (STC) plus growth-coupled adaptive laboratory evolution (ALE) to force P. putida to grow on methanol alone, reaching a ~40h doubling time. This is a real and carefully executed piece of synthetic biology, using whole-genome sequencing, reverse genetics, biosensors, isotope tracing and RNA-seq to identify seven convergent mutations. However, the headline claim of 'first demonstration of strict synthetic methylotrophy in P. putida' is complicated by the same group's own earlier, peer-reviewed work: Turlin et al. (mBio, 2025, PMID pending/DOI 10.1128/mbio.01976-25) already achieved strict methylotrophic P. putida growth on methanol via the reductive glycine pathway, with a faster doubling time (~24h) than the STC route now being reported. A related peer-reviewed paper from the same group, Puiggene et al. (Trends in Biotechnology, 2025, PMID 40617716), laid out the modular engineering of synthetic serine cycle variants in P. putida. In other words, this is the same lab iterating across at least two competing synthetic C1 pathways in the same host, and the 'first' framing should be read as first-via-this-specific-cycle, not first synthetic methylotrophy in P. putida overall. The broader scientific field of synthetic methylotrophy is active and crowded: independent groups have engineered E. coli (RuMP cycle, hybrid Mdh/Das pathway, PMID 36704306), Komagataella phaffii (RuMP cycle, PMID 41791454; CBB-cycle autotrophy, PMID 41317844), and Saccharomyces cerevisiae (self-reprogrammed ASrG pathway, PMID 39705340; energy-efficient AOX pathway, Nat Commun 2026 PMID 41547665) to grow on methanol or CO2 using conceptually similar ALE-plus-multi-omics strategies. This means the general mechanism class (synthetic autocatalytic C1 cycle + growth-coupled evolution) is well validated across multiple independent labs and organisms, which supports plausibility, but the specific P. putida/STC result is preprint-only and has not been independently replicated by a group outside Nikel's own team. Critically for an investment lens, this is an academic research program, not a company. There is no disclosed spinout entity, no funding round, no named CEO or business team, no patent filings identified in Lens.org searches, and no clinical/industrial trial registrations (expected, since this is industrial biotech rather than a therapeutic). The evolved strain's ~40h doubling time is roughly 15-20x slower than wild-type P. putida, and the paper explicitly frames it as a functional proof-of-concept, not a production-relevant strain. There is no product titer, yield, or scale-up data of any kind for an actual bio-based chemical. Commercially, there is precedent for methanol/methane-based biomanufacturing at scale using natural methylotrophs (e.g., single-cell protein production from Pichia pastoris at pilot scale, PMID 37770920; natural methanotroph-based feed protein commercialized by companies like Calysta and Unibio), which establishes market demand for C1-feedstock bioproducts. But no synthetic (engineered, non-native) methylotroph has yet reached commercial production at scale in any organism, and P. putida specifically remains multiple engineering generations away from an industrially relevant growth rate or product pathway. Given the complete absence of a corporate structure, funding disclosure, or IP position, this opportunity should currently be assessed as a research program to potentially license or fund a spinout from, not as a company ready for direct capital deployment.